A1H89N
Top-News
ONCOSEC MEDICAL steigt auf über 2 Dollar
Beiträge:
71
Zugriffe: 19.280 / Heute: 2
Zugriffe: 19.280 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +60,99%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +48,35%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +45,76%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +45,57%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +43,46%
OncoSec Establishes Clinical Site for Its Phase II Metastatic Melanoma Trial at University of Washington University of Washington To Become Fourth Enrolling Center in Trial
PR Newswire
SAN DIEGO, Sept. 25, 2012
SAN DIEGO, Sept. 25, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100). Investigational Review Board (IRB) approval has been received by UW, and investigators are actively recruiting for this clinical trial.
(Logo: photos.prnewswire.com/prnh/20120905/LA68078LOGO)
"UW now joins the University of California, San Francisco, John Wayne Cancer Institute and Lakeland Cancer Center as our fourth site for the melanoma study," said Punit Dhillon, President and CEO of OncoSec. "We have enjoyed working with UW and Dr. Shailender Bhatia for the Merkel cell carcinoma program, and look forward to having them join the melanoma trial as well."
A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
Dr. Shailender Bhatia, principal investigator at UW, commented "We have had experience with this treatment in the Phase II Merkel cell carcinoma study, so we are glad to have the opportunity to now offer this treatment as an experimental therapy to the patients who are suffering from melanoma."
ImmunoPulse utilizes OncoSec's proprietary technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The OncoSec Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using ImmunoPulse to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.
For more information about this trial visit: clinicaltrials.gov/ct2/show/NCT01502293.
PR Newswire
SAN DIEGO, Sept. 25, 2012
SAN DIEGO, Sept. 25, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100). Investigational Review Board (IRB) approval has been received by UW, and investigators are actively recruiting for this clinical trial.
(Logo: photos.prnewswire.com/prnh/20120905/LA68078LOGO)
"UW now joins the University of California, San Francisco, John Wayne Cancer Institute and Lakeland Cancer Center as our fourth site for the melanoma study," said Punit Dhillon, President and CEO of OncoSec. "We have enjoyed working with UW and Dr. Shailender Bhatia for the Merkel cell carcinoma program, and look forward to having them join the melanoma trial as well."
A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
Dr. Shailender Bhatia, principal investigator at UW, commented "We have had experience with this treatment in the Phase II Merkel cell carcinoma study, so we are glad to have the opportunity to now offer this treatment as an experimental therapy to the patients who are suffering from melanoma."
ImmunoPulse utilizes OncoSec's proprietary technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The OncoSec Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using ImmunoPulse to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.
For more information about this trial visit: clinicaltrials.gov/ct2/show/NCT01502293.
NEW ARSENAL IN CANCER WAR
San Diego’s OncoSec Medical is testing treatment that uses electronic pulses to activate fight against tumors
Comments ()Share:TweetFacebookEmailPrintSave By PADMA NAGAPPAN SPECIAL TO THE U-T
12:01 a.m., Oct. 3, 2012
Updated 7:09 p.m. , Oct. 2, 2012
CEO Punit Dhillon, 32, with an electroporator at OncoSec Medical. Nelvin C. Cepeda • U-t Late-stage skin cancers are typically treated with chemotherapy and surgery, but a San Diego company is focusing on a noninvasive approach that it says will improve the quality of life for patients.
OncoSec Medical is conducting Phase 2 clinical trials for a therapy called Immunopulse, which taps the body’s immune response to destroy cancer cells. By delivering short electrical pulses to the surface of a tumor, it targets the cells more accurately, boosting the effectiveness of the anti-cancer agent it delivers.
“I’ve watched this market and how you deliver drugs to tumors. Increasing the payload helps improve effectiveness, but it also increases toxicity. What this company is doing is targeting the localized tumor,” said Duane Roth, chief executive of Connect, the San Diego tech incubator that assisted OncoSec. “It’s ‘how do you increase the payload and get the immune system to respond.’ ”
With nearly $12 million in funding, OncoSec is conducting simultaneous Phase 2 clinical trials for Immunopulse for three types of cancer: metastatic melanoma, Merkel cell carcinoma and cutaneous T-Cell lymphoma. The three are less common than other skin cancers but are often drug-resistant and aggressive.
Immunopulse combines the electrical pulses, called electroporation, with gene therapy. The technology was developed by Inovio Pharmaceuticals in San Diego, which focuses on DNA-based vaccines for infectious diseases and oncology.
When the combination proved promising in skin cancers, it led to the formation of OncoSec in March 2011. Punit Dhillon, who was Inovio’s vice president of finance and operations, founded OncoSec, which acquired the rights to the technology and the device.
Dhillon’s uncle, Avtar Dhillon, current chairman of Inovio, is the company’s other co-founder.
Tap protein that kills cells Electroporation opens temporary pores in the cell membrane of infected cells, through which an anti-cancer agent can be transmitted more effectively. OncoSec’s therapy uses a gene that triggers secretion of a protein that targets and kills the cancerous cells.
Previously, researchers have introduced genes into tumors using viruses, but that technique has drawbacks, such as biohazard concerns, risk of spreading and immune response concerns.
“When you keep injecting viruses, then the immune system mounts an attack against the virus itself, so whatever gene you are introducing with the virus will have less chance of getting a response,” said Dr. Adil Daud, an oncologist who runs OncoSec’s clinical trial for metastatic melanoma and is a co-investigator in the other trials.
Electroporation does not have that issue, said Daud, who is co-director of the melanoma program at the University of California San Francisco.
“It’s a great modality for treatment. You inject the naked DNA or gene into the cell and get the gene to be expressed in that tumor so it gets an immune reaction and destroys the tumor,” he said.
The process of applying the electrical pulse can be unpleasant for patients, but the reaction recedes quickly, Daud said. Side effects are limited to fever, chills and possible minimal short-term pain.
Treatment can be given on an outpatient basis, with the process taking just a few minutes three times over eight days.
San Diego’s OncoSec Medical is testing treatment that uses electronic pulses to activate fight against tumors
Comments ()Share:TweetFacebookEmailPrintSave By PADMA NAGAPPAN SPECIAL TO THE U-T
12:01 a.m., Oct. 3, 2012
Updated 7:09 p.m. , Oct. 2, 2012
CEO Punit Dhillon, 32, with an electroporator at OncoSec Medical. Nelvin C. Cepeda • U-t Late-stage skin cancers are typically treated with chemotherapy and surgery, but a San Diego company is focusing on a noninvasive approach that it says will improve the quality of life for patients.
OncoSec Medical is conducting Phase 2 clinical trials for a therapy called Immunopulse, which taps the body’s immune response to destroy cancer cells. By delivering short electrical pulses to the surface of a tumor, it targets the cells more accurately, boosting the effectiveness of the anti-cancer agent it delivers.
“I’ve watched this market and how you deliver drugs to tumors. Increasing the payload helps improve effectiveness, but it also increases toxicity. What this company is doing is targeting the localized tumor,” said Duane Roth, chief executive of Connect, the San Diego tech incubator that assisted OncoSec. “It’s ‘how do you increase the payload and get the immune system to respond.’ ”
With nearly $12 million in funding, OncoSec is conducting simultaneous Phase 2 clinical trials for Immunopulse for three types of cancer: metastatic melanoma, Merkel cell carcinoma and cutaneous T-Cell lymphoma. The three are less common than other skin cancers but are often drug-resistant and aggressive.
Immunopulse combines the electrical pulses, called electroporation, with gene therapy. The technology was developed by Inovio Pharmaceuticals in San Diego, which focuses on DNA-based vaccines for infectious diseases and oncology.
When the combination proved promising in skin cancers, it led to the formation of OncoSec in March 2011. Punit Dhillon, who was Inovio’s vice president of finance and operations, founded OncoSec, which acquired the rights to the technology and the device.
Dhillon’s uncle, Avtar Dhillon, current chairman of Inovio, is the company’s other co-founder.
Tap protein that kills cells Electroporation opens temporary pores in the cell membrane of infected cells, through which an anti-cancer agent can be transmitted more effectively. OncoSec’s therapy uses a gene that triggers secretion of a protein that targets and kills the cancerous cells.
Previously, researchers have introduced genes into tumors using viruses, but that technique has drawbacks, such as biohazard concerns, risk of spreading and immune response concerns.
“When you keep injecting viruses, then the immune system mounts an attack against the virus itself, so whatever gene you are introducing with the virus will have less chance of getting a response,” said Dr. Adil Daud, an oncologist who runs OncoSec’s clinical trial for metastatic melanoma and is a co-investigator in the other trials.
Electroporation does not have that issue, said Daud, who is co-director of the melanoma program at the University of California San Francisco.
“It’s a great modality for treatment. You inject the naked DNA or gene into the cell and get the gene to be expressed in that tumor so it gets an immune reaction and destroys the tumor,” he said.
The process of applying the electrical pulse can be unpleasant for patients, but the reaction recedes quickly, Daud said. Side effects are limited to fever, chills and possible minimal short-term pain.
Treatment can be given on an outpatient basis, with the process taking just a few minutes three times over eight days.
oncosec.com/index.php/corporate-governance/analyst-coverage/
ih.advfn.com/...riod=0&drawmode=0&size=19&volume=1
oncosec.com/index.php/corporate-governance/analyst-coverage/
mein ziel sind 5 ( FÜNF ) DOLLAR
.
oncosec.com/index.php/corporate-governance/analyst-coverage/
mein ziel sind 5 ( FÜNF ) DOLLAR
.
oncosec.com/index.php/corporate-governance/analyst-coverage/
oh my God
www2.barchart.com/opinions/stocks/ONCS
www2.barchart.com/opinions/stocks/ONCS
After Hours: $ 0,26 0,00 (0.00%) Volume: 3 k 16:00 EDT 08.10.2012
nachbörslich 780 DOLLAR ist nicht die Welt
allerdings hatten wir das schon lange nicht mehr
nachbörslich 780 DOLLAR ist nicht die Welt
allerdings hatten wir das schon lange nicht mehr
OncoSec Establishes Clinical Site for Its Phase II Metastatic Melanoma Trial at University of Washington University of Washington To Become Fourth Enrolling Center in Trial
PR Newswire
SAN DIEGO, Sept. 25, 2012
SAN DIEGO, Sept. 25, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100). Investigational Review Board (IRB) approval has been received by UW, and investigators are actively recruiting for this clinical trial.
(Logo: photos.prnewswire.com/prnh/20120905/LA68078LOGO)
"UW now joins the University of California, San Francisco, John Wayne Cancer Institute and Lakeland Cancer Center as our fourth site for the melanoma study," said Punit Dhillon, President and CEO of OncoSec. "We have enjoyed working with UW and Dr. Shailender Bhatia for the Merkel cell carcinoma program, and look forward to having them join the melanoma trial as well."
A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
Dr. Shailender Bhatia, principal investigator at UW, commented "We have had experience with this treatment in the Phase II Merkel cell carcinoma study, so we are glad to have the opportunity to now offer this treatment as an experimental therapy to the patients who are suffering from melanoma."
ImmunoPulse utilizes OncoSec's proprietary technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The OncoSec Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using ImmunoPulse to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.
For more information about this trial visit: clinicaltrials.gov/ct2/show/NCT01502293.
PR Newswire
SAN DIEGO, Sept. 25, 2012
SAN DIEGO, Sept. 25, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100). Investigational Review Board (IRB) approval has been received by UW, and investigators are actively recruiting for this clinical trial.
(Logo: photos.prnewswire.com/prnh/20120905/LA68078LOGO)
"UW now joins the University of California, San Francisco, John Wayne Cancer Institute and Lakeland Cancer Center as our fourth site for the melanoma study," said Punit Dhillon, President and CEO of OncoSec. "We have enjoyed working with UW and Dr. Shailender Bhatia for the Merkel cell carcinoma program, and look forward to having them join the melanoma trial as well."
A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
Dr. Shailender Bhatia, principal investigator at UW, commented "We have had experience with this treatment in the Phase II Merkel cell carcinoma study, so we are glad to have the opportunity to now offer this treatment as an experimental therapy to the patients who are suffering from melanoma."
ImmunoPulse utilizes OncoSec's proprietary technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The OncoSec Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using ImmunoPulse to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.
For more information about this trial visit: clinicaltrials.gov/ct2/show/NCT01502293.
www.maxblue.de/de/...ml?symbol=ONCS.NAP&isin=US68234L1089
Preisfeststellungen ziehen an
heuer wurden schlappe 269735,96 DOLLAR gehandelt
zuzüglich After Hours: 780 DOLLAR
Preisfeststellungen ziehen an
heuer wurden schlappe 269735,96 DOLLAR gehandelt
zuzüglich After Hours: 780 DOLLAR
investorshub.advfn.com/OncoSec-Medical-Inc-ONCS-20508/
marketplayground.com/2012/09/27/...ch-gem-oncs-alxa-bpax-vtus/
OncoSec Medical to Present Data at Two Upcoming Conferences Company to Present at SITC 2012 and 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres/8th EADO Congress
PR Newswire
SAN DIEGO, Oct. 09, 2012
SAN DIEGO, Oct. 09, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapies to treat solid tumor cancers, announced the company will be presenting data at two upcoming medical conferences.
(Logo: photos.prnewswire.com/prnh/20120905/LA68078LOGO)
Dr. Shailender Bhatia, assistant professor at the University of Washington School of Medicine, will be presenting preliminary clinical data from OncoSec's ongoing Phase II Merkel cell carcinoma trial at the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2012), October 26-28, 2012, at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Maryland.
The company will also be presenting preliminary clinical data from its ongoing Phase II metastatic melanoma trial to the 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres/8th EADO Congress, November 14-17, 2012, at the Hotel Fira Palace in Barcelona, Spain.
Preliminary analyses of both the Merkel cell carcinoma and metastatic melanoma trials will be based on a subset of enrolled subjects, and will evaluate clinical response to at least one cycle of ImmunoPulse treatment.
At the Melanoma/EADO meeting on November 15 at 5:30 PM local Barcelona time, Adil I. Daud, M.D., co-director of melanoma clinical research at the University of California San Francisco's Helen Diller Family Comprehensive Cancer Center and lead investigator for OncoSec's metastatic melanoma trial, along with Axel Hauschild, M.D., professor of dermatology at the University of Kiel, will co-chair an OncoSec-sponsored symposium titled "Electrogenetherapy: Intralesional Immunotherapy Approach for Skin Cancers Using Electroporation."
The company will provide a complete summary of the data presented at both conferences in upcoming press releases.
About SITC 2012
The SITC Annual Meeting & Associated Programs serve as the premier destination for scientific exchange, education and networking in the cancer immunotherapy community. Basic researchers, clinicians, students, postdoctoral fellows and allied health professionals dedicated to improving cancer patient outcomes come together to experience cutting edge research, education and training that serves as the catalyst to advance the field.
About the 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres/8th EADO Congress
The World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers is an opportunity for clinicians and researchers who are part of multidisciplinary melanoma centers can interact, learn from one another, establish collaborations and set an agenda for the further evolution of multidisciplinary melanoma care and research. The meeting has been combined with the EADO congress whose focus is on melanoma, cutaneous lymphoma and epithelial skin cancers and is specifically designed to attract young investigators and skin cancer-treating physicians in the field.
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at www.oncosec.com/.
PR Newswire
SAN DIEGO, Oct. 09, 2012
SAN DIEGO, Oct. 09, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapies to treat solid tumor cancers, announced the company will be presenting data at two upcoming medical conferences.
(Logo: photos.prnewswire.com/prnh/20120905/LA68078LOGO)
Dr. Shailender Bhatia, assistant professor at the University of Washington School of Medicine, will be presenting preliminary clinical data from OncoSec's ongoing Phase II Merkel cell carcinoma trial at the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2012), October 26-28, 2012, at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Maryland.
The company will also be presenting preliminary clinical data from its ongoing Phase II metastatic melanoma trial to the 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres/8th EADO Congress, November 14-17, 2012, at the Hotel Fira Palace in Barcelona, Spain.
Preliminary analyses of both the Merkel cell carcinoma and metastatic melanoma trials will be based on a subset of enrolled subjects, and will evaluate clinical response to at least one cycle of ImmunoPulse treatment.
At the Melanoma/EADO meeting on November 15 at 5:30 PM local Barcelona time, Adil I. Daud, M.D., co-director of melanoma clinical research at the University of California San Francisco's Helen Diller Family Comprehensive Cancer Center and lead investigator for OncoSec's metastatic melanoma trial, along with Axel Hauschild, M.D., professor of dermatology at the University of Kiel, will co-chair an OncoSec-sponsored symposium titled "Electrogenetherapy: Intralesional Immunotherapy Approach for Skin Cancers Using Electroporation."
The company will provide a complete summary of the data presented at both conferences in upcoming press releases.
About SITC 2012
The SITC Annual Meeting & Associated Programs serve as the premier destination for scientific exchange, education and networking in the cancer immunotherapy community. Basic researchers, clinicians, students, postdoctoral fellows and allied health professionals dedicated to improving cancer patient outcomes come together to experience cutting edge research, education and training that serves as the catalyst to advance the field.
About the 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres/8th EADO Congress
The World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers is an opportunity for clinicians and researchers who are part of multidisciplinary melanoma centers can interact, learn from one another, establish collaborations and set an agenda for the further evolution of multidisciplinary melanoma care and research. The meeting has been combined with the EADO congress whose focus is on melanoma, cutaneous lymphoma and epithelial skin cancers and is specifically designed to attract young investigators and skin cancer-treating physicians in the field.
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at www.oncosec.com/.
ih.advfn.com/...riod=0&drawmode=0&size=19&volume=1
Last Change Change % Volume Last-Trade Time Open High Low
0.3195 0.0255 8.67 1,702,060 10/10/12 12:44:16 0.314 0.325 0.301
0.3195 0.0255 8.67 1,702,060 10/10/12 12:44:16 0.314 0.325 0.301
oncosec.com/index.php/corporate-governance/analyst-coverage/
2nd Resistance Point 0.3573
1st Resistance Point 0.3257
Last Price 0.3195
1st Resistance Point 0.3257
Last Price 0.3195
www2.barchart.com/opinions/stocks/ONCS
ih.advfn.com/...bol=ONCS&period=0&size=19&volume=1
investorshub.advfn.com/boards/board.aspx?board_id=20508
bemerkenswert ist, dass drüben kaum einer postet
bemerkenswert ist, dass drüben kaum einer postet
oncosec.com/index.php/corporate-governance/analyst-coverage/
After Hours: $ 0,38 0,01 (+2.70%) Volume: 14,3 k 16:00 EDT 10.10.2012
seekingalpha.com/article/...nts-to-start-the-week?source=yahoo
Marktkapitalisierung 32,51 Mio
es wurden 1,44 Mio. Dollar gehandelt
es wurden 1,44 Mio. Dollar gehandelt
seekingalpha.com/article/...sec-ceo-punit-dhillon?source=yahoo
OncoSec Medical Inc. (ONCS): Pushing the Limits of Cancer Treatment
No CommentsPosted 15 Oct 2012
Category Biotechnology and Drugs, Healthcare, Investing, Market News, ONCS, Sectors, Stocks, Trading By The Swiss Trader
Recently, the San Francisco Chronicle carried a story about a promising treatment for melanoma at the University of California, San Francisco (UCSF). UCSF is one of three cancer centers in the U.S. testing electroImmunotherapy, a form of electroporation using an immunotherapy therapy as its agent of choice, in clinical trials for the treatment of melanoma. Cancer patient David Amoroso has been receiving treatment since March, after a mole on his forehead turned into a late-stage melanoma tumor, leaving him with a 24% chance of survival. Had he reached the next stage, metastatic melanoma, his chance of survival would have been reduced to 10% to 15%. Instead of opting for conventional treatment and drugs, he volunteered to undergo ElectroImmunotherapy treatment. Results have been positive so far, as four out of his six visible tumors seem to have vanished. The treatment is weeks from proving completely effective and years from being commercially available, according to Adil Daud, the trial’s chief investigator and co-director of UCSF’s Melanoma Program. But he said, “I think it has a lot of potential for the future.”
The studies are being sponsored by OncoSec Medical Inc. (OTC:ONCS), a San Diego, Claifornia based biotech company that is developing the technology. OncoSec is also testing the treatment on two other rare and aggressive skin cancers: Merkel cell carcinoma and T-cell lymphoma. When Amoroso receives the treatment, he is first given an injection in the area around the tumor with interleukin-12 (IL-12) plasmid DNA. An electroporation device is connected to six electrodes which are inserted into the targeted tumor and marginal tissue. The device then briefly applies 1300 volts to the tissue. Within a few microseconds, the electrical charge opens the cellular membrane pores of the cancer cells and allows them to absorb the pre-injected IL-12 plasmid. When the current is turned off, the pores reseal and trap the agent inside. Once inside the cells, the absorbed IL-12 plasmid then instructs the cells to produce IL-12 which sends a warning to the body’s immune system about the presence of harmful tumor cells. Immune cells will then attack and destroy the cells with the IL-12 expression, a novel targeting concept by the ElectroImmunotherapy technology. The treatment procedure is over in seconds, and none of the nine patients have reported any side effects. One melanoma patient in the trial has not responded, but the other eight have seen most, if not all, of their tumors shrink. These nine patients have enrolled in the trial because they had tried surgery or drugs which did not work.
OncoSec Medical is developing its proprietary electroporation platform called OMS as a delivery system for anti-cancer agents. It has two separate approaches using its OMS platform. The first approach utilizing IL-12 is called ElectroImmunotherapy, branded as ImmunoPulse. The second approach, called ElectroChemotherapy and branded as NeoPulse, delivers an approved chemotherapy drug called bleomycin to the tumor or cancer site. Because this is a drug delivery system, the company believes that there is potential to deliver many varieties of approved anti-cancer drugs. The company has seen an uptake improvement of up to 4,000 times in the absorption of the agent relative to traditional injection methodologies. This means that effectiveness is increased, and much less of the agent needs to be used, thus minimizing side effects.
In a recent interview, OncoSec Medical CEO and president, Punit Dhillon, provided an update on recent developments. The company has completed analysis of the phase III head and neck cancer data, and presented these results at this year’s International Head and Neck Cancer Conference in Toronto in July. It is currently evaluating the extensive database of information obtained from both the phase 3 and 4 NeoPulse trials pertaining to the pharmacoeconomic benefits of the therapy, and results are expected to be published in the first quarter of 2013. Because of OncoSec’s limited resources, there is a strong focus on the ImmunoPulse program as the company appears to be making the most of its funding, a positive for investors as the company is careful to not overstep its financial boundaries. For the NeoPulse program, the focus is to present data to a number of specifically chosen potential partners to enable them to evaluate the licensing opportunities. The company believes that this could be a near-term commercial opportunity, and that if an agreement can be reached with a partner, it would be a significant validation of the data and program. With respect to the ImmunoPulse program, interim analysis of data for the phase II trials is currently being carried out for both the melanoma trial (OMS-I100) and the Merkel cell carcinoma trial (OMS-I110), and results are expected to be presented by the end of 2012.
The company has had encouraging results on safety and efficacy, and the CEO stated that its phase 1 data is best-in-class for any metastatic melanoma program in history. The company has met every milestone that it has set since inception, and enrollment expectations have been exceeded for every program. Important milestones coming up this year include interim data from the melanoma and Merkel cell program, along with updates on potential deals relating to the NeoPulse program. He adds that the company’s positioning in the cancer immunotherapy space is unique. For years, scientists have concluded that the cause of many cancers is a dysfunctional immune system, thus leading to the development of new agents. The problem, however, has been the inability to deliver these agents effectively while maintaining acceptable levels of safety for the patient. Moreover, the treatment is cost-effective because it has the potential to be administered in an outpatient clinic.
OncoSec Medical is unlike many other early stage biotech companies, which are often dependent on the successful development and commercialization of one new drug. The good news for ONCS investors is that OncoSec Medical is not developing a new drug, but a drug delivery system that uses already approved drugs. The company is hedging its bets by developing two lines of treatment on its OMS platform, NeoPulse and ImmunoPulse. Many of the usual risks of investing in the biotech sector are mitigated, though the company must still obtain the necessary regulatory approvals and commercialize the treatment successfully. OncoSec Medical is currently trading around $0.25, between a 52-week range of $0.12 and $1.00. I believe investors looking for exposure to potentially groundbreaking cancer treatments should consider OncoSec Medical now, as this stock will likely trade several multiples higher upon new successful developments of either of its new treatments.
Disclosure: Long ONCS
No CommentsPosted 15 Oct 2012
Category Biotechnology and Drugs, Healthcare, Investing, Market News, ONCS, Sectors, Stocks, Trading By The Swiss Trader
Recently, the San Francisco Chronicle carried a story about a promising treatment for melanoma at the University of California, San Francisco (UCSF). UCSF is one of three cancer centers in the U.S. testing electroImmunotherapy, a form of electroporation using an immunotherapy therapy as its agent of choice, in clinical trials for the treatment of melanoma. Cancer patient David Amoroso has been receiving treatment since March, after a mole on his forehead turned into a late-stage melanoma tumor, leaving him with a 24% chance of survival. Had he reached the next stage, metastatic melanoma, his chance of survival would have been reduced to 10% to 15%. Instead of opting for conventional treatment and drugs, he volunteered to undergo ElectroImmunotherapy treatment. Results have been positive so far, as four out of his six visible tumors seem to have vanished. The treatment is weeks from proving completely effective and years from being commercially available, according to Adil Daud, the trial’s chief investigator and co-director of UCSF’s Melanoma Program. But he said, “I think it has a lot of potential for the future.”
The studies are being sponsored by OncoSec Medical Inc. (OTC:ONCS), a San Diego, Claifornia based biotech company that is developing the technology. OncoSec is also testing the treatment on two other rare and aggressive skin cancers: Merkel cell carcinoma and T-cell lymphoma. When Amoroso receives the treatment, he is first given an injection in the area around the tumor with interleukin-12 (IL-12) plasmid DNA. An electroporation device is connected to six electrodes which are inserted into the targeted tumor and marginal tissue. The device then briefly applies 1300 volts to the tissue. Within a few microseconds, the electrical charge opens the cellular membrane pores of the cancer cells and allows them to absorb the pre-injected IL-12 plasmid. When the current is turned off, the pores reseal and trap the agent inside. Once inside the cells, the absorbed IL-12 plasmid then instructs the cells to produce IL-12 which sends a warning to the body’s immune system about the presence of harmful tumor cells. Immune cells will then attack and destroy the cells with the IL-12 expression, a novel targeting concept by the ElectroImmunotherapy technology. The treatment procedure is over in seconds, and none of the nine patients have reported any side effects. One melanoma patient in the trial has not responded, but the other eight have seen most, if not all, of their tumors shrink. These nine patients have enrolled in the trial because they had tried surgery or drugs which did not work.
OncoSec Medical is developing its proprietary electroporation platform called OMS as a delivery system for anti-cancer agents. It has two separate approaches using its OMS platform. The first approach utilizing IL-12 is called ElectroImmunotherapy, branded as ImmunoPulse. The second approach, called ElectroChemotherapy and branded as NeoPulse, delivers an approved chemotherapy drug called bleomycin to the tumor or cancer site. Because this is a drug delivery system, the company believes that there is potential to deliver many varieties of approved anti-cancer drugs. The company has seen an uptake improvement of up to 4,000 times in the absorption of the agent relative to traditional injection methodologies. This means that effectiveness is increased, and much less of the agent needs to be used, thus minimizing side effects.
In a recent interview, OncoSec Medical CEO and president, Punit Dhillon, provided an update on recent developments. The company has completed analysis of the phase III head and neck cancer data, and presented these results at this year’s International Head and Neck Cancer Conference in Toronto in July. It is currently evaluating the extensive database of information obtained from both the phase 3 and 4 NeoPulse trials pertaining to the pharmacoeconomic benefits of the therapy, and results are expected to be published in the first quarter of 2013. Because of OncoSec’s limited resources, there is a strong focus on the ImmunoPulse program as the company appears to be making the most of its funding, a positive for investors as the company is careful to not overstep its financial boundaries. For the NeoPulse program, the focus is to present data to a number of specifically chosen potential partners to enable them to evaluate the licensing opportunities. The company believes that this could be a near-term commercial opportunity, and that if an agreement can be reached with a partner, it would be a significant validation of the data and program. With respect to the ImmunoPulse program, interim analysis of data for the phase II trials is currently being carried out for both the melanoma trial (OMS-I100) and the Merkel cell carcinoma trial (OMS-I110), and results are expected to be presented by the end of 2012.
The company has had encouraging results on safety and efficacy, and the CEO stated that its phase 1 data is best-in-class for any metastatic melanoma program in history. The company has met every milestone that it has set since inception, and enrollment expectations have been exceeded for every program. Important milestones coming up this year include interim data from the melanoma and Merkel cell program, along with updates on potential deals relating to the NeoPulse program. He adds that the company’s positioning in the cancer immunotherapy space is unique. For years, scientists have concluded that the cause of many cancers is a dysfunctional immune system, thus leading to the development of new agents. The problem, however, has been the inability to deliver these agents effectively while maintaining acceptable levels of safety for the patient. Moreover, the treatment is cost-effective because it has the potential to be administered in an outpatient clinic.
OncoSec Medical is unlike many other early stage biotech companies, which are often dependent on the successful development and commercialization of one new drug. The good news for ONCS investors is that OncoSec Medical is not developing a new drug, but a drug delivery system that uses already approved drugs. The company is hedging its bets by developing two lines of treatment on its OMS platform, NeoPulse and ImmunoPulse. Many of the usual risks of investing in the biotech sector are mitigated, though the company must still obtain the necessary regulatory approvals and commercialize the treatment successfully. OncoSec Medical is currently trading around $0.25, between a 52-week range of $0.12 and $1.00. I believe investors looking for exposure to potentially groundbreaking cancer treatments should consider OncoSec Medical now, as this stock will likely trade several multiples higher upon new successful developments of either of its new treatments.
Disclosure: Long ONCS
marketplayground.com/2012/10/15/...limits-of-cancer-treatment/
OncoSec Receives CE Mark for Its Electroporation DevicePublished: October 17, 2012
2012-10-17T10:16:36Z
OncoSec Medical Incorporated
0 Comments
E-mail
Print Recent HeadlinesCinegif Teams with PulseConnect to Visually Improve Email Marketing
10 minutes ago
Schwedelson Elected to the DMA Board of Directors
10 minutes ago
Bergamo Acquisition’s CEO Does Radio Interview - Provides Update
10 minutes ago
Circadence Listed as an Innovator in Info-Tech Research Group’s WAN Optimization Vendor Landscape
10 minutes ago
Pennsylvania’s Indiana Area School District Selects Constellation for Approximately $16 Million in Facility Improvements
10 minutes ago
Deals!
$10 for $20 worth of food and drinks!
Coupons View All
DentalWorks
$29 exam and x-ray
KFC
Hungry man meal $7.99
Shrimp Boat
Buy one dinner get one for $1Search for Deals
Search local inventory, coupons and more
Powered by
Photos & Videos
Brent Venables at Oct. 16 press conference...
Sammy Watkins at Clemson press conference...
Friday Knight's Losers, week 9
Emmett Scott Recreation Center Surveillance video of attack suspects McClatchy cartoons for the week of 10... Organ restored at First ARP Local barber celebrates 55 years cutting...
Paws in the Park Rock Hill at South Pointe 10.12.12 Paws in the Park 10.13.12 South Pointe blanks Rock Hill
Fort Mill at Northwestern Tropical Escape owners prepare to close... Clover veteran may avoid more jail time Sheriff's deputies win national shooting...
Winthrop men's basketball coach Pat Kelsey... Winthrop women's basketball at Big South... Deputies win at national rifle competition... Friday Knight's Losers, week 8
MORE > Videos Photos Submit Your Photos CE Certification Enables Commercialization of OncoSec Medical System (OMS) Electroporation Device in European Economic Area
By OncoSec Medical Incorporated SAN DIEGO, Oct. 17, 2012 — /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse drug-based chemotherapy to treat solid tumor cancers, announced it has received authorization to CE mark its proprietary gene and drug delivery platform, the OncoSec Medical System (OMS) electroporation device, for use in the European Economic Area (EEA). SGS Group, an industry-leading inspection, verification, testing and certification company, supervised the assessment and certification process.(Logo: photos.prnewswire.com/prnh/20120905/LA68078LOGO)A CE mark verifies the OMS electroporation device has met all applicable directives of the European Commission (EC) and subsequently the laws and regulations of the European Union (EU) member states and therefore can be commercialized within the 30-nation EEA and Switzerland. The electroporation device applies short electric impulses to a tumor, causing pores to open in the membrane of cancer cells, significantly increasing the uptake of anti-cancer agents into these cells. The granting of this CE mark involved a comprehensive audit of the company's quality system as well as thorough evaluation and testing of the OMS electroporation device to assure it performs safely and as designed. The CE mark affirms OncoSec's commitment to product quality and development, and augments the notified body certification to the International Organization for Standardization's (ISO) 13485 standard for the "design, development, manufacture, and distribution of electroporation devices," which the company received in July.Punit Dhillon, President and CEO of OncoSec, commented, "The approval marks an essential regulatory milestone on the road to commercialization and further approval of the OncoSec Medical System. The CE mark shows that OncoSec has the capability to manufacture and develop a device that meets commercial regulatory requirements."About OncoSec Medical Inc.OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at www.oncosec.com/. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. SOURCE OncoSec Medical Incorporated
Read more here: www.heraldonline.com/2012/10/17/4342711/....html#storylink=cpy
2012-10-17T10:16:36Z
OncoSec Medical Incorporated
0 Comments
Print Recent HeadlinesCinegif Teams with PulseConnect to Visually Improve Email Marketing
10 minutes ago
Schwedelson Elected to the DMA Board of Directors
10 minutes ago
Bergamo Acquisition’s CEO Does Radio Interview - Provides Update
10 minutes ago
Circadence Listed as an Innovator in Info-Tech Research Group’s WAN Optimization Vendor Landscape
10 minutes ago
Pennsylvania’s Indiana Area School District Selects Constellation for Approximately $16 Million in Facility Improvements
10 minutes ago
Deals!
$10 for $20 worth of food and drinks!
Coupons View All
DentalWorks
$29 exam and x-ray
KFC
Hungry man meal $7.99
Shrimp Boat
Buy one dinner get one for $1Search for Deals
Search local inventory, coupons and more
Powered by
Photos & Videos
Brent Venables at Oct. 16 press conference...
Sammy Watkins at Clemson press conference...
Friday Knight's Losers, week 9
Emmett Scott Recreation Center Surveillance video of attack suspects McClatchy cartoons for the week of 10... Organ restored at First ARP Local barber celebrates 55 years cutting...
Paws in the Park Rock Hill at South Pointe 10.12.12 Paws in the Park 10.13.12 South Pointe blanks Rock Hill
Fort Mill at Northwestern Tropical Escape owners prepare to close... Clover veteran may avoid more jail time Sheriff's deputies win national shooting...
Winthrop men's basketball coach Pat Kelsey... Winthrop women's basketball at Big South... Deputies win at national rifle competition... Friday Knight's Losers, week 8
MORE > Videos Photos Submit Your Photos CE Certification Enables Commercialization of OncoSec Medical System (OMS) Electroporation Device in European Economic Area
By OncoSec Medical Incorporated SAN DIEGO, Oct. 17, 2012 — /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse drug-based chemotherapy to treat solid tumor cancers, announced it has received authorization to CE mark its proprietary gene and drug delivery platform, the OncoSec Medical System (OMS) electroporation device, for use in the European Economic Area (EEA). SGS Group, an industry-leading inspection, verification, testing and certification company, supervised the assessment and certification process.(Logo: photos.prnewswire.com/prnh/20120905/LA68078LOGO)A CE mark verifies the OMS electroporation device has met all applicable directives of the European Commission (EC) and subsequently the laws and regulations of the European Union (EU) member states and therefore can be commercialized within the 30-nation EEA and Switzerland. The electroporation device applies short electric impulses to a tumor, causing pores to open in the membrane of cancer cells, significantly increasing the uptake of anti-cancer agents into these cells. The granting of this CE mark involved a comprehensive audit of the company's quality system as well as thorough evaluation and testing of the OMS electroporation device to assure it performs safely and as designed. The CE mark affirms OncoSec's commitment to product quality and development, and augments the notified body certification to the International Organization for Standardization's (ISO) 13485 standard for the "design, development, manufacture, and distribution of electroporation devices," which the company received in July.Punit Dhillon, President and CEO of OncoSec, commented, "The approval marks an essential regulatory milestone on the road to commercialization and further approval of the OncoSec Medical System. The CE mark shows that OncoSec has the capability to manufacture and develop a device that meets commercial regulatory requirements."About OncoSec Medical Inc.OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at www.oncosec.com/. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. SOURCE OncoSec Medical Incorporated
Read more here: www.heraldonline.com/2012/10/17/4342711/....html#storylink=cpy
oncosec.com/index.php/corporate-governance/analyst-coverage/
ih.advfn.com/...chart&s=NB^ONCS&p=0&t=19&vol=1
ih.advfn.com/...chart&s=NB^ONCS&p=0&t=19&vol=1
investorshub.advfn.com/boards/breakoutboards.aspx
investorshub.advfn.com/boards/breakoutboards.aspx
investorshub.advfn.com/boards/read_msg.aspx?message_id=80699035
www.maxblue.de/de/maerkte-aktie.html?symbol=ONCS.NAP
www.maxblue.de/de/...ml?symbol=ONCS.NAP&isin=US68234L1089
www.wallstreet-online.de/nachricht/...agg-pink-nsrgy-pink-pwei
OncoSec Medical, Inc. (ONCS.OB) appears to be one of the best-kept secrets in the biotech sector.
Support & Resistance More
2nd Resistance Point 0.5170
1st Resistance Point 0.4841
2nd Resistance Point 0.5170
1st Resistance Point 0.4841
www.boerse-berlin.de/index.php/Aktien?isin=US68234L1089
ab sofort ist der Handel in Berlin möglich
www.boerse-berlin.de/index.php/Aktien?isin=US68234L1089
www.boerse-berlin.de/index.php/Aktien?isin=US68234L1089
oncosec.com/index.php/corporate-governance/analyst-coverage/
Rahul Jasuga auf über 5 Dollar ?
Rahul Jasuga auf über 5 Dollar ?
app.quotemedia.com/quotetools/...;cp=off&webmasterId=89753
ih.advfn.com/...chart&s=NB^ONCS&p=0&t=19&vol=1
www.otcmarkets.com/stock/ONCS/quote
Eine wichtiger Meilenstein für Oncosec:
OncoSec, UCSF, and Merck Initiate a Landmark Phase IIb Combination Trial of Breakthrough Drug KEYTRUDA® And ImmunoPulse to Treat Metastatic Melanoma
http://punitdhillon.com/2014/11/25/...e-to-treat-metastatic-melanoma/
bin gespannt wie die amis reagieren
www.businesswire.com/news/home/...ration-Evaluate#.VORzUC7adGE
www.businesswire.com/news/home/...ration-Evaluate#.VORzUC7adGE
PR NEWSWIRE 1:09 PM ET 5/27/2015
SAN DIEGO , May 27, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") , a company developing DNA-based intratumoral cancer immunotherapies, today announced the company has received approval to begin trading its common stock on The NASDAQ Stock Market LLC. OncoSec's common stock will begin trading on The NASDAQ Stock Market LLC at the opening of market hours on Friday, May 29.
"Over the past year, our team has made significant headway to build a strong, cutting-edge, clinical stage biotech company. As we become a NASDAQ-listed company, we are now able to communicate our progress with a broader audience, raise the visibility of OncoSec's capabilities, and generate more value for our shareholders," said Punit Dhillon, President and CEO of OncoSec. "We are now in a better position to continue to advance our intratumoral immunotherapy technologies with the goal of one day benefiting cancer patients everywhere."
OncoSec Medical Announces FINRA Approval of Reverse Stock Split
Alert
OncoSec Medical Incorporated (USOTC:ONCSD)
Historical Stock Chart
1 Month : From Apr 2015 to May 2015
SAN DIEGO, May 15, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Financial Industry Regulatory Authority ("FINRA") has approved the company's 1-for-20 reverse stock split. According to FINRA's approval, the reverse stock split will become effective and OncoSec's common stock will begin trading on a post-split basis before the open of trading on May 18, 2015.
www.analystratings.com/articles/...g-on-oncosec-medical-oncs/
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem OncoSec Medical Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 70 | ONCOSEC MEDICAL steigt auf über 2 Dollar | wikki 1 | Balu4u | 15.06.21 11:44 | |
| 28 | OncoSec Medical Incorporated (ONCS) | Chalifmann3 | Svenny | 25.04.21 02:25 | ||
| 5 | Hab ich wohl ein bischen zu teuer gekauft | wilhelmo1 | wilhelmo1 | 10.05.17 22:12 |